Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple
diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom. The company trades on AIM exchange marketplace. The company headquarter is located in United Kingdom. The company was established in the 2015. As of writing, the company status seems to be inactive, which indicates it may not be actively trading on the stock exchanges and may be delisted/merged/suspended/renamed.
| Ticker | EVG |
| Long Name | Evgen Pharma PLC |
| Short Name | Evgen Pharma |
| Sector | Healthcare |
| Subsector | Biotechnology |
| Subsector 2 | Health Care |
| Currency | GBX |
| ISIN | |